Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,238 INR | +3.35% | +6.55% | +11.22% |
Mar. 27 | Ipca Laboratories Licenses Anti-Cancer Biosimilar Technology to Omexa Formulary | MT |
Feb. 19 | Nomura Adjusts IPCA Laboratories Price Target to INR1,308 From INR1,113, Keeps at Buy | MT |
Sales 2024 * | 75.72B 909M | Sales 2025 * | 89.16B 1.07B | Capitalization | 314B 3.77B |
---|---|---|---|---|---|
Net income 2024 * | 6.28B 75.31M | Net income 2025 * | 9.55B 115M | EV / Sales 2024 * | 4.29 x |
Net Debt 2024 * | 10.66B 128M | Net Debt 2025 * | 4.51B 54.18M | EV / Sales 2025 * | 3.57 x |
P/E ratio 2024 * |
48.2
x | P/E ratio 2025 * |
33
x | Employees | 16,167 |
Yield 2024 * |
0.37% | Yield 2025 * |
0.46% | Free-Float | 52.35% |
Latest transcript on Ipca Laboratories Limited
1 day | +3.35% | ||
1 week | +6.55% | ||
Current month | +3.87% | ||
1 month | +3.69% | ||
3 months | +16.98% | ||
6 months | +34.20% | ||
Current year | +11.22% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 68 | 80-04-01 | |
Pranay Godha
CEO | Chief Executive Officer | 51 | 03-04-15 |
Chairman | 77 | 75-10-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 77 | 75-10-30 | |
Director/Board Member | 76 | 11-08-15 | |
Pranay Godha
CEO | Chief Executive Officer | 51 | 03-04-15 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 1,238 | +3.35% | 65 795 |
24-03-27 | 1,198 | -0.25% | 14,090 |
24-03-26 | 1,201 | +0.31% | 9,307 |
24-03-22 | 1,197 | +2.06% | 13,594 |
24-03-21 | 1,173 | +0.95% | 5,388 |
Delayed Quote Bombay S.E., March 28, 2024 at 06:00 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+33.46% | 701B | |
+26.24% | 571B | |
+0.93% | 381B | |
+21.03% | 334B | |
+17.51% | 319B | |
+0.74% | 210B | |
+2.95% | 210B | |
-6.05% | 201B | |
-3.61% | 157B |
- Stock
- Equities
- Stock Ipca Laboratories Limited
- Stock Ipca Laboratories Limited - Bombay S.E.